Misplaced Pages

Zicronapine

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Atypical antipsychotic medication Pharmaceutical compound
Zicronapine
Identifiers
IUPAC name
  • 4--1,2,2-trimethylpiperazine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27ClN2
Molar mass354.92 g·mol
3D model (JSmol)
SMILES
  • Clc1ccc4c(c1)(N2CC(N(C)CC2)(C)C)C4c3ccccc3
InChI
  • InChI=1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1
  • Key:BYPMJBXPNZMNQD-PZJWPPBQSA-N

Zicronapine (/zaɪˈkrɒnəpiːn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic Lu AF35700 (a prodrug of Lu AF356152).

References

  1. Citrome L (November 2013). "A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach". CNS Drugs. 27 (11): 879–911. doi:10.1007/s40263-013-0105-7. PMID 24062193. S2CID 23867019.
  2. "The clinical phase III programme commenced on zicronapine". January 20, 2011. Archived from the original on 2 February 2017. Retrieved 6 February 2014.
  3. "Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work". December 18, 2009. Archived from the original on 8 October 2016. Retrieved 6 February 2014.
  4. "Performance in 2014 positions Lundbeck well for 2015 and beyond" (PDF). February 5, 2015. Archived from the original (PDF) on 18 June 2015. Retrieved 18 June 2015.

External links

Antipsychotics (N05A)
Typical
Disputed
Atypical
Others
Dopamine receptor modulators
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Serotonin receptor modulators
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This psychiatry-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Zicronapine Add topic